GlySure Inks $10.9M Series C
GlySure Ltd., a U.K.-based developer of in-hospital continuous blood glucose monitoring systems, has raised $10.9 million in fresh capital. The company will use the Series C round, led by Morningside Venture, to complete clinical trials and seek regulatory approval. Existing shareholders Amadeus Capital Partners, Chester Investments and Delta Partners also participated in the round. GlySure has raised a total of $19.5 million in venture backing.
10 January 2012•2 mins read
